Abstract

Antibody cocktails represent a promising approach to prevent SARS-CoV-2 escape. The determinants for selecting antibody combinations and the mechanism that antibody cocktails prevent viral escape remain unclear. We compared the critical residues in the receptor-binding domain (RBD) used by multiple neutralizing antibodies and cocktails and identified a combination of two antibodies CoV2-06 and CoV2-14 for preventing viral escape. The two antibodies simultaneously bind to non-overlapping epitopes and independently compete for receptor binding. SARS-CoV-2 rapidly escapes from individual antibodies by generating resistant mutations in vitro, but it doesn’t escape from the cocktail due to stronger mutational constraints on RBD-ACE2 interaction and RBD protein folding requirements. We also identified a conserved neutralizing epitope shared between SARS-CoV-2 and SARS-CoV for antibody CoV2-12. Treatments with CoV2-06 and CoV2-14 individually and in combination confer protection in mice. These findings provide insights for rational selection and mechanistic understanding of antibody cocktails as candidates for treating COVID-19.

Antibody cocktails represent a promising approach to prevent SARS-CoV-2 escape. Here, Ku et al., identify SARS-CoV-2 neutralizing antibodies from a phage library and identify an antibody combination that prevents viral escape and protects mice from viral challenge.

Details

Title
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Author
Ku Zhiqiang 1 ; Xie Xuping 2   VIAFID ORCID Logo  ; Davidson, Edgar 3 ; Ye Xiaohua 1 ; Su, Hang 1 ; Menachery, Vineet D 4   VIAFID ORCID Logo  ; Li Yize 5 ; Yuan Zihao 1 ; Zhang, Xianwen 2 ; Muruato, Antonio E 2 ; i Escuer Ariadna Grinyo 3 ; Tyrell Breanna 3 ; Doolan, Kyle 3 ; Doranz, Benjamin J 3   VIAFID ORCID Logo  ; Wrapp, Daniel 6   VIAFID ORCID Logo  ; Bates, Paul F 5 ; McLellan, Jason S 6   VIAFID ORCID Logo  ; Weiss, Susan R 5 ; Zhang Ningyan 1   VIAFID ORCID Logo  ; Pei-Yong, Shi 2   VIAFID ORCID Logo  ; An, Zhiqiang 1   VIAFID ORCID Logo 

 University of Texas Health Science Center at Houston, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, USA (GRID:grid.267308.8) (ISNI:0000 0000 9206 2401) 
 University of Texas Medical Branch, Department of Biochemistry and Molecular Biology, Institute for Human Infection and Immunity, Sealy Institute for Vaccine Sciences, Sealy Center for Structural Biology & Molecular Biophysics, Department of Pharmacology & Toxicology, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964) 
 Integral Molecular, Philadelphia, Pennsylvania, USA (GRID:grid.281032.a) 
 University of Texas Medical Branch, Department of Microbiology & Immunology, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964) 
 University of Pennsylvania, Department of Microbiology, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Texas at Austin, Department of Molecular Biosciences, Austin, USA (GRID:grid.89336.37) (ISNI:0000 0004 1936 9924) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2547166531
Copyright
© The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.